Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) Will Announce Quarterly Sales of $77.59 Million

Wall Street analysts expect Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to post $77.59 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Pacira Pharmaceuticals’ earnings, with the highest sales estimate coming in at $80.06 million and the lowest estimate coming in at $75.21 million. Pacira Pharmaceuticals reported sales of $72.90 million in the same quarter last year, which indicates a positive year over year growth rate of 6.4%. The firm is scheduled to announce its next earnings report on Wednesday, March 7th.

On average, analysts expect that Pacira Pharmaceuticals will report full year sales of $77.59 million for the current year, with estimates ranging from $282.76 million to $297.60 million. For the next year, analysts expect that the business will report sales of $329.89 million per share, with estimates ranging from $312.29 million to $357.10 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. The business had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The firm’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 EPS.

A number of research firms have issued reports on PCRX. Mizuho reiterated a “buy” rating and set a $53.00 target price (down previously from $54.00) on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. Goldman Sachs Group initiated coverage on Pacira Pharmaceuticals in a report on Thursday, September 28th. They issued a “neutral” rating and a $41.00 price objective for the company. Canaccord Genuity restated a “buy” rating and issued a $44.00 price objective (down previously from $48.00) on shares of Pacira Pharmaceuticals in a report on Sunday, October 1st. Needham & Company LLC restated a “buy” rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 26th. Finally, Zacks Investment Research upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Tuesday, October 3rd. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $48.86.

Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $44.20 on Tuesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24. Pacira Pharmaceuticals has a 1-year low of $29.81 and a 1-year high of $58.95.

In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld purchased 1,000 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was bought at an average cost of $41.60 per share, for a total transaction of $41,600.00. Following the completion of the transaction, the director now owns 6,795 shares in the company, valued at $282,672. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP James B. Jones sold 850 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $41.11, for a total transaction of $34,943.50. The disclosure for this sale can be found here. Insiders have sold 69,735 shares of company stock valued at $2,692,594 over the last 90 days. Company insiders own 6.60% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Oppenheimer Asset Management Inc. bought a new position in Pacira Pharmaceuticals in the second quarter valued at approximately $114,000. Cubist Systematic Strategies LLC increased its stake in Pacira Pharmaceuticals by 121.5% in the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after acquiring an additional 1,752 shares during the last quarter. QS Investors LLC bought a new position in Pacira Pharmaceuticals in the second quarter valued at approximately $157,000. Ameritas Investment Partners Inc. increased its stake in Pacira Pharmaceuticals by 9.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after acquiring an additional 302 shares during the last quarter. Finally, Spectrum Management Group Inc. bought a new position in Pacira Pharmaceuticals in the third quarter valued at approximately $166,000.

COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) Will Announce Quarterly Sales of $77.59 Million” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/12/12/brokerages-anticipate-pacira-pharmaceuticals-inc-pcrx-will-announce-quarterly-sales-of-77-59-million.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply